2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.74: Real-World Data on Non-Small Cell Lung Cancer Treated With First-Line Checkpoint Inhibitors in a Latin American Institution

PP01.74: Real-World Data on Non-Small Cell Lung Cancer Treated With First-Line Checkpoint Inhibitors in a Latin American Institution

Back to course

Pdf Summary

This study analyzes real-world data from a Latin American institution on advanced non-small cell lung cancer (NSCLC) patients treated with first-line checkpoint inhibitors (CPI) from 2015 to 2023. Conducted at the Oncosalud-AUNA cancer center in Lima, Peru, the study offers critical insights beyond randomized clinical trials, particularly due to their stringent eligibility criteria which do not always reflect everyday clinical settings.<br /><br />The patient population comprised 89 individuals with a median age of 68 years, predominantly male (56.2%), and primarily adenocarcinoma cases (88.8%). Most patients had never smoked (52.9%) and had a performance status of 1 (81.6%) or 2 (16.1%). Treatments included CPIs alone (28.1%), CPIs with chemotherapy (69.7%), and CPIs with chemotherapy and bevacizumab (2.2%).<br /><br />Key outcomes highlighted include a median follow-up of 50.4 months, with a median progression-free survival (PFS) of 12 months and an overall survival (OS) of 14.4 months. The study found the median OS was 7.2 months for pembrolizumab monotherapy, 10.8 months for atezolizumab combined with chemotherapy, and 20.4 months for pembrolizumab combined with chemotherapy. The objective response rate (ORR) was 48.8%, with stable disease reported in 22.5% and progressive disease in 28.8% of cases.<br /><br />The findings demonstrate that pembrolizumab plus chemotherapy’s OS in this real-world setting aligns with RCT results, while atezolizumab plus chemotherapy and immunotherapy alone showed lower median OS than reported in RCTs. Immune-related adverse events occurred in 37.1% of patients, highlighting the need for deeper investigation into these outcomes and their underlying causes. Thus, this study enhances understanding of CPI treatment efficacy and challenges in NSCLC beyond controlled trial environments.

Asset Subtitle

Tania Paytán Rivera

Keywords

NSCLC

checkpoint inhibitors

real-world data

Oncosalud-AUNA

pembrolizumab

atezolizumab

chemotherapy

progression-free survival

overall survival

immune-related adverse events